Diagnostic Testing Market Analysis 2013-2018 with Industry Chain Structure, Competitive Landscape
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments.
The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Request For Sample of this Report available at http://www.rnrmarketresearch.com/contacts/request-sample?rname=457309
List of Tables
Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments 14
Table 1.2: Market Trends in the High-Growth Diagnostics Space 16
Table 1.3: Worldwide Geographic Distribution of Total IVD Testing Market, 2011 18
Table 1.4: Top 13 Country IVD Testing Markets, 2011 18
Table 1.5: Company Market Share for IVD Testing Markets, 2011 19
Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 20
Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018 21
Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 21
Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 22
Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections 32
Table 3.2: Lower Detection Limits of HBV DNA Assays 33
Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology 37
Table 3.4: Global Revenue Forecasts for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018 39
Table 3.5: Global Revenue Forecasts for Hepatitis B Virus (HBV) Diagnostic Testing, 2008-2018 40
Table 3.6: Efficiency of Available HCV Screening Tests 44
Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C 45
Table 3.8: Hepatitis C Statistics 46
Table 3.9: Novartis Diagnostics Clinical Diagnostic Products Test for the Detection of HCV 47
Table 3.10: Global Revenue Forecasts for Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018 49
Table 4.1: HPV Risk Factors 50
Table 4.2: HPV and Cervical Carcinoma 51
Table 4.3: Key statistics on Cervical Cancer in the World, 2011 52
Table 4.4: Reflex HPV Testing with Cytology 57
Table 4.5: Predictability of HPV Test by Abnormal Pap Smear Type 57
Table 4.6: Long-Term Trends in HPV Testing 58
Table 4.7: Global Revenue Forecasts for Human Papillomavirus (HPV) Diagnostic Testing, 2008-2018 58
Table 5.1: Global HIV Statistics, 2009 62
Table 5.2: Antiretroviral Therapy (ART) Coverage, 2008 63
Table 5.3: Estimated Number of HIV Infection, 2009 64
Table 5.4: Estimated Number of AIDS Infection, 2009 64
Table 5.5: Drivers of Demand for HIV Diagnostic Testing 65
Table 5.6: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact 66
Table 5.7: Drivers of Demand for HIV Diagnostic Testing 66
Table 5.8: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact 66
Table 5.9: Selected POC Infectious Disease Testing Devices, 2011 70
Table 5.10: Global Revenue Forecasts for HIV and AIDS Diagnostic Testing, 2008-2018 72
Table 5.11: Competitive Factors Related to HIV Tests 74
Table 6.1: Rapid Strep Tests on the Market 84
Table 6.2: Rapid Tests for Chlamydia 88
Table 6.3: Rapid Tests for Gonorrhea 92
Table 6.4: Commercially-available Rapid Tests for Malaria 102
Table 6.5: Estimated TB Incidence, Prevalence and Mortality, 2009 105
Table 6.6: FIND Partners 110
Table 6.7: Global Market Potential for TB Diagnostic Testing, 2000-2010 112
Table 6.8: MRSA Diagnostics Currently on the Market 114
Table 6.9: Global Revenue Infectious Disease Revenue Analysis, 2008-2018 115
Table 7.1: Medication Chart for Cardiovascular Disease 120
Table 7.2: BNP Clinical Characteristics 124
Table 7.3: Cardiovascular Risk Classification by CRP Level 129
Table 7.4: Clinical Characteristics of D-dimer 129
Table 7.5: Global Revenue Forecasts for Cardiac Marker Testing, 2008-2018 138
Table 8.1: Genetic Testing: Consequences and Challenges 143
Table 8.2: CF Carrier Risk by Ethnic Group 143
Table 8.3: Reasons for CF Testing 144
Table 8.4: CF Gene Detection Rates Vary by Ethnic Background 145
Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018 146
Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018 146
Table 8.7: Commercial CF Screening Products 147
Table 8.8: Emerging CF Screening Products 147
Table 9.1: The Fertility Testing Market in the U.S., 2008-2018 149
Table 10.1: Estimated Numbers of New Cases for Selected Cancers in the U.S., 2012 154
Table 10.2: Five-Year Disease-free Survival by Stage at Diagnosis 155
Table 10.3: TPA Marker Sensitivity 164
Table 10.4: INFINITI Applications 178
Table 10.5: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018 179
Table 11.1: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department 185
Table 11.2: Stat Urine Testing Drug Recommendations 186
Table 11.3: Selected POC Substance/Drug Abuse Testing Devices, 2011 190
Table 11.4: Selected POC Substance/Drug Abuse Testing Devices, OraSure, 2011 198
Table 11.5: Selected Target Substances and Drugs, 2011 199
Table 11.6: Global Revenue Forecasts for Substance Abuse Testing, 2008-2018 203
Table 12.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018 208
Table 14.1: Global Revenue Forecasts for Companion Diagnostics, 2008-2018 212
Table 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011 213
Table 15.2: Top 13 Country IVD Testing Markets, 2011 214
Table 15.3: Company Market Share for IVD Testing Markets, 2011 215
Table 15.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 216
Table 15.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 216
Table 15.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 217
Table 15.7: Summary of IVD High-Growth Market U.S., 2011 218
Table 15.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018 218
Table 15.9: U.S. Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 219
Table 15.10: U.S. Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 219
Table 15.11: Specific Cardiac Markers 220
Table 15.12: Cardiac Markers after Onset of Myocardial Infarction 221
Table 15.13: U.S. Cardiac Marker Revenue Forecasts, 2008-2018 223
Table 15.14: Market Share of Cardiac Marker Segment 223
Table 15.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe, 2008-2018 227
Table 15.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 228
Table 15.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 228
Table 15.18: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018 232
Table 15.19: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 232
Table 15.20: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 233
Table 15.21: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018 234
Table 15.22: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 235
Table 15.23: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 235
Table 15.24: Overview of Healthcare in India 237
Table 15.25: Population Projections India 239
Table 15.26: Statistical Healthcare Data India 239
Table 15.27: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018 244
Table 15.28: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 244
Table 15.29: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 245
Table 15.30: Number of Healthcare Institutions According to Ownership China, 2010 247
Table 15.31: Total Number of Hospitals by Ranking China, 2010 248
Table 15.32: Disease Burden in China: Urban and Rural 249
Table 15.33: China Biotech Reagents Market 257
Table 15.34: Biotechnology Projects Between China and the West 258
Table 15.35: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018 262
Table 15.36: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 262
Table 15.37: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 263
Table 15.38: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia, 2008-2018 271
Table 15.39: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018 272
Table 15.40: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 272
Table 17.1: Estimated Cervical Cancer Cases/Deaths Worldwide, 2011 286
Table 17.2: Medicare Reimbursement for Cervical Pathology Procedures 290
Table 18.1: New CPT Test Codes Introduced in 2008 301
Table 19.1: Employment of Clinical Laboratory Workers, 2006-2016 309
Table 21.1: Common Genotype Techniques 319
Table 22.1: Applications for Wireless LAN Technology 331
Table 22.2: Customized Reports Must Support CAP and JCAHO Requirements 335
Table 22.3: RALS-Plus Point of Care Market Share 336
Table 22.4: Applications of RALS Connectivity with POCT Devices 336
Table 23.1: Biochip Revenues and Growth Rates by Application, 2003 and 2007 344
Table 23.2: Total Biochip Market: Worldwide Revenue Forecasts, 2008-2018 349
Table 23.3: Total Biochip Market: U.S. Revenue Forecasts, 2008-2018 349
Table 24.1: Abaxis, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010 358
Table 24.2: Abaxis, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010 359
Table 24.3: Abbott Laboratories Financial Figures—Net Sales by Business Sector, 2008-2010 360
Table 24.4: Abbott Laboratories Financial Figures—Net Sales by Geographic Region, 2008-2010 360
Table 24.5: Alere, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010 364
Table 24.6: Alere, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010 365
Table 24.7: Bayer AG Financial Figures—Net Sales by Business Sector, 2008-2010 372
Table 24.8: Bayer AG Financial Figures—Net Sales by Geographic Region, 2008-2010 372
Table 24.9: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010 377
Table 24.10: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010 378
Table 24.11: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses, 2008-2010 388
Table 24.12: Quidel Product Sales Distribution and Sales, 2009 and 2010 403
Table 24.13: Danaher Corporation Financial Figures—Net Sales by Business Sector, 2008-2010 407
Table 24.14: Danaher Corporation Financial Figures—Net Sales by Geographic Region, 2008-2010 407
Table 24.15: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2010 411
Table 24.16: Roche Group Financial Figures—Net Sales by Geographic Region, 2009 and 2010 411
Table 24.17: Roche Group Financial Figures—Net Sales by Sub-Division, 2008-2010 411
Purchase This Report Online at http://www.rnrmarketresearch.com/contacts/purchase?rname=457309
List of Figures
Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011 18
Figure 1.2: Top 13 Country IVD Testing Markets, 2011 19
Figure 1.3: Company Market Share for IVD Testing Markets, 2011 19
Figure 3.1: Evolution of HBV Markers in Acute and Chronic Infection 36
Figure 6.1: Global Incidence of Malaria 96
Figure 6.2: Mode of Action of Common Malaria RDT Format 99
Figure 6.3: FIND Pipeline for TB Diagnostics 109
Figure 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011 214
Figure 15.2: Top 13 Country IVD Testing Markets, 2011 215
Figure 15.3: Company Market Share for IVD Testing Markets, 2011 215
Figure 15.4: Indian Diagnostics Market Segments, 2011 240
Figure 15.5: The Chinese Healthcare System 246
Figure 17.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females, 2011 284
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact Us:
We provide 24/7 online and offline support to our customers. Contact us for your special interest needs and we will get in touch within 24hrs to help you find the market research report you need.
[email protected]
+ 1 888 391 5441
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).